Macclesfield, United Kingdom

Christine Marie Paul Lambert-Van Der Brempt

USPTO Granted Patents = 7 


Average Co-Inventor Count = 5.6

ph-index = 3

Forward Citations = 28(Granted Patents)


Location History:

  • Reims, Cedex, FR (2013)
  • Reims, FR (2013 - 2014)
  • Cheshire, GB (2015)
  • Macclesfield, GB (2015 - 2017)

Company Filing History:


Years Active: 2013-2017

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: Christine Marie Paul Lambert-Van Der Brempt: Innovator in Pharmaceutical Chemistry

Introduction

Christine Marie Paul Lambert-Van Der Brempt is a distinguished inventor based in Macclesfield, GB. She has made significant contributions to the field of pharmaceutical chemistry, holding a total of seven patents. Her work focuses on developing innovative chemical compounds that have the potential to treat various cell proliferative disorders.

Latest Patents

Among her latest patents are the chromenone derivatives, which concern chromenone derivatives of Formula I or pharmaceutically-acceptable salts thereof. These compounds are designed for use in the manufacture of medicaments aimed at treating cell proliferative disorders. Another notable patent involves chemical compounds of Formula (I) or pharmaceutically-acceptable salts, which also target the treatment of cell proliferative disorders.

Career Highlights

Christine is currently associated with AstraZeneca AB, a leading global biopharmaceutical company. Her role at AstraZeneca has allowed her to contribute to groundbreaking research and development in the pharmaceutical industry.

Collaborations

Throughout her career, Christine has collaborated with notable colleagues, including Patrick Ple and Sebastien Louis Degorce. These collaborations have further enhanced her research and innovation in the field.

Conclusion

Christine Marie Paul Lambert-Van Der Brempt exemplifies the spirit of innovation in pharmaceutical chemistry. Her contributions through her patents and collaborations continue to impact the treatment of critical health conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…